• Education
  • Points
  •  Download App
  • Country
    singapore
    hong kong
    malaysia
    indonesia
    thailand
    philippines
    vietnam
    india

    australia
    korea
    new zealand
The MIMS logo.
  • Home
  • Find Drugs
  • Pill Identifier
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The MIMS logo.
  • Home
  • Find Drugs
  • Pill Identifier
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The MIMS logo.
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates

Other Services
 Education
 Points
  Download App
Country
singapore
hong kong
malaysia
indonesia
thailand
vietnam
india
australia
korea
new zealand
Account
The MIMS logo.
  1. Diseases
  2. Acromegaly
  3. ...
    • Diseases
    • Acromegaly
  4. Follow Up

Acromegaly Follow Up

Last updated: 27 January 2025
Reviewed by
test fredtest 3test 4test 6test test 7 é tes é MIMS Endocrinology Honorary Editorial Advisory Board
Disease SummaryDrug SummaryDisease AlgorithmDisease BackgroundInitial AssessmentDiagnosticsDifferential DiagnosisManagementFollow UpReferences
Follow Up
  • Disease Summary
  • Drug Summary
  • Disease Algorithm
  • Disease Background
  • Initial Assessment
  • Diagnostics
  • Differential Diagnosis
  • Management
  • References
Follow up
Content:
Monitoring

Content on this page:

Monitoring

Content on this page:

Monitoring

Monitoring

During the first postoperative year, IGF-1 measurements may be done every 3 to 6 months to confirm remission, then every 6 to 12 months to monitor for recurrence. The comparison of early random GH measurement on days 1 to 14 postsurgery with preoperative GH levels can determine degree of adenoma removal and subsequent long-term remission. OGTT can be added when evaluating patients with borderline IGF-1 levels and signs of disease activity. For patients who did not achieve postoperative remission and those treated with adjuvant SRL, IGF-1 should be assessed 3 months after initiation or dose titration of injectable SRLs and 2 to 4 weeks after initiation or dose titration of oral SRL to establish dosing regimen, then every 6 to 12 months thereafter. For patients on Pegvisomant or Cabergoline, IGF-1 should be measured every 1 to 3 months after initiation or dose titration to establish dosing regimen, then every 6 to 12 months thereafter. Lastly, MRI should be performed at 3 to 6 months postoperatively, if there are signs of biochemical or clinical disease progression, and when change in therapeutic modality is considered (eg prior to repeat surgery or radiotherapy).

The MIMS logo.
  • Drugs
  • Find Drugs
  • Pill Identifier
  • Find Drug Company
  • MIMS Abbreviation Index
  • Diseases
  • Search Disease Information
  • Editorial Advisory Board
  • Medical News & Updates
  • Latest News & Updates
  • More Services
  • Education
  • Points
  • Subscribe
  • About
  • MIMS Corporate
  • Terms of Use
  • Privacy Policy
  • Feedback
Connect with MIMS
A social media brand icon.A social media brand icon.
TUV Nord ISO 9001 certification logo
MIMS Specialty merge/stg-2.1-uat-2.2-22-Oct_1962.1
Copyright © 2025 MIMS Pte Ltd. All rights reserved. SIT
MIMS Logo

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?
Something went wrong.